From: The burden of hepatitis C in Europe from the patients’ perspective: a survey in 5 countries
HCV group | Unmatched controls | Matched controls | ||||||
---|---|---|---|---|---|---|---|---|
(n = 286) | (n = 56,880) | (n = 286) | ||||||
Mean | SD | Mean | SD | p-value* | Mean | SD | p-value† | |
Work impairment | ||||||||
Absenteeism | 7.78% | 19.16% | 5.44% | 19.20% | <.001 | 5.45% | 20.34% | .010 |
Presenteeism | 26.27% | 27.58% | 15.83% | 22.79% | <.001 | 14.45% | 21.58% | <.001 |
Overall work impairment | 30.45% | 31.42% | 19.39% | 27.70% | <.001 | 18.30% | 27.47% | <.001 |
Activity impairment | 34.37% | 30.60% | 24.38% | 28.16% | <.001 | 28.46% | 30.57% | .011 |
Healthcare use | ||||||||
Annual physician visits | 19.80 | 23.93 | 10.66 | 14.64 | <.001 | 13.26 | 19.21 | <.001 |
Annual ER visits | 0.68 | 2.11 | 0.38 | 1.90 | .006 | 0.39 | 1.19 | .330 |
Annual hospitalizations | 0.52 | 1.59 | 0.26 | 2.14 | <.001 | 0.27 | 0.98 | .073 |
Quality of life (SF-12v2) | ||||||||
MCS | 44.17 | 9.85 | 46.58 | 10.59 | <.001 | 46.36 | 10.79 | .012 |
PCS | 43.61 | 10.14 | 48.67 | 9.75 | <.001 | 46.09 | 10.33 | .004 |
Health utility | 0.67 | 0.12 | 0.73 | 0.13 | <.001 | 0.71 | 0.15 | .001 |